[{"id":"fdd64cda-9a21-415b-a112-87e898241472","acronym":"BGB-3245-AU-001","url":"https://clinicaltrials.gov/study/NCT04249843","created_at":"2021-01-18T20:39:09.280Z","updated_at":"2025-02-25T16:32:04.976Z","phase":"Phase 1","brief_title":"Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants with Advanced or Refractory Tumors","source_id_and_acronym":"NCT04249843 - BGB-3245-AU-001","lead_sponsor":"MapKure, LLC","biomarkers":" KRAS • BRAF • NRAS","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion","tags":["KRAS • BRAF • NRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • BRAF V600 • BRAF fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e brimarefenib (BGB-3245)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 02/17/2020","start_date":" 02/17/2020","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2025-02-07"},{"id":"458ece6c-2e33-4eb0-a2a0-8ea765fec664","acronym":"","url":"https://clinicaltrials.gov/study/NCT06194877","created_at":"2024-01-08T19:20:10.802Z","updated_at":"2024-07-02T16:34:37.787Z","phase":"Phase 1","brief_title":"A Study to Investigate BGB-3245 (Brimarafenib) With Panitumumab in Participants With Advanced or Metastatic RAS Mutant Colorectal and Pancreatic Ductal Cancers","source_id_and_acronym":"NCT06194877","lead_sponsor":"MapKure, LLC","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vectibix (panitumumab) • brimarefenib (BGB-3245)"],"overall_status":"Recruiting","enrollment":" Enrollment 64","initiation":"Initiation: 04/18/2024","start_date":" 04/18/2024","primary_txt":" Primary completion: 05/24/2027","primary_completion_date":" 05/24/2027","study_txt":" Completion: 05/24/2027","study_completion_date":" 05/24/2027","last_update_posted":"2024-06-06"}]